Key result
Senescent endothelial EVs worsen heart failure by delivering miR-503 to suppress mitophagy via MST1.
Why the study?
The role of miR-503 carried by extracellular vesicles from senescent endothelial cells in modulating m6A modification and mitochondrial dysfunction in heart failure was investigated.
Does miR-503 delivered by senescent endothelial cell-derived extracellular vesicles exacerbate mitochondrial dysfunction and heart failure by modulating MST1 m6A modification in doxorubicin-treated rats and cardiomyocytes?
Does miR-503 delivered by senescent endothelial cell-derived extracellular vesicles exacerbate mitochondrial dysfunction and heart failure by modulating MST1 m6A modification in doxorubicin-treated rats and cardiomyocytes?
Preclinical evidence demonstrates that senescent endothelial cell-derived extracellular vesicles deliver miR-503 to cardiomyocytes to alter MST1 m6A methylation, thereby suppressing mitophagy and exacerbating doxorubicin-induced heart failure.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in doxorubicin cardiotoxicity models; leaves open human relevance of endothelial EV effects on mitophagy.
This study investigates the role of miR-503 in mitochondrial dysfunction related to heart failure (HF), specifically how it is carried by extracellular vesicles from senescent endothelial cells (EVs senescent ), affecting m6A modification in cardiomyocytes. A rat model of endothelial cell senescence was used to produce EVs senescent . HF was induced in rats using doxorubicin (DOX) and treated with EVs senescent , EVs miR-503 antagomir , and DAA. Cardiac function, tissue fibrosis, and NT-proBNP levels were assessed using echocardiography, histological staining, and ELISA, respectively. Mitochondrial markers TOM20 and LC3B were analyzed. DOX-treated H9C2 cells were developed as a cell model, with mitophagy, mitochondrial function, cell viability, and the levels of marker proteins and miR-503 measured. Total m6A was quantified, and m6A methylation sites on MST1 mRNA were predicted and subsequently validated. EVs senescent showed high miR-503, inhibiting mitophagy and promoting mitochondrial dysfunction, thereby worsening HF in rats. These effects were partially reversed by miR-503 antagomir. EVs senescent miR-503 repressed mitophagy and increased mitochondrial dysfunction in DOX-treated cardiomyocytes. Mitophagy activation reduced the adverse effects of EVs senescent . An m6A methylation site on MST1 was identified. miR-503 delivered by EVs senescent was correlated with MST1/m6A modification and mitochondrial dysfunction. EVs senescent miR-503 to modulate MST1 expression in an m6A modification-dependent manner, thereby suppressing mitophagy, aggravating mitochondrial dysfunction, and exacerbating HF in rats.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2026) studied Doxorubicin-induced heart failure (preclinical rat model) (n=48). Senescent endothelial cell-derived extracellular vesicles (EVs_senescent), EVs_miR-503 antagomir, and 3-deazaadenosine (DAA) vs. Saline control and untreated doxorubicin-induced heart failure model groups was evaluated on Mitophagy, mitochondrial dysfunction, MST1 m6A modification, and cardiac function in heart failure (p=<0.001). Senescent endothelial cell-derived EVs deliver miR-503 to modulate MST1 m6A methylation, suppressing mitophagy and exacerbating mitochondrial dysfunction and heart failure in rats.
Synapse has enriched 10 related papers. Consider them for comparative context: